GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (MEX:BIIB) » Definitions » EPS (Basic)

Biogen (MEX:BIIB) EPS (Basic) : MXN136.10 (TTM As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Biogen EPS (Basic)?

Biogen's basic earnings per share (Basic EPS) for the three months ended in Mar. 2024 was MXN44.98. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2024 was MXN136.10.

Biogen's EPS (Diluted) for the three months ended in Mar. 2024 was MXN44.81. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was MXN135.43.

Biogen's EPS without NRI for the three months ended in Mar. 2024 was MXN49.77. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2024 was 244.70.

During the past 12 months, Biogen's average EPS without NRIGrowth Rate was -13.50% per year. During the past 3 years, the average EPS without NRI Growth Rate was -11.10% per year. During the past 5 years, the average EPS without NRI Growth Rate was -11.10% per year. During the past 10 years, the average EPS without NRI Growth Rate was 5.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Biogen's highest 3-Year average EPS without NRI Growth Rate was 159.00% per year. The lowest was -61.90% per year. And the median was 22.90% per year.


Biogen EPS (Basic) Historical Data

The historical data trend for Biogen's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen EPS (Basic) Chart

Biogen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 593.52 494.52 214.17 408.64 136.13

Biogen Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 48.49 70.12 -8.19 29.20 44.98

Biogen EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Biogen's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(19708.799-0)/144.700
=136.20

Biogen's Basic EPS for the quarter that ended in Mar. 2024 is calculated as

Basic EPS (Q: Mar. 2024 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(6528.967-0)/145.200
=44.97

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN136.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biogen  (MEX:BIIB) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Biogen EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Biogen's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (MEX:BIIB) Business Description

Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.

Biogen (MEX:BIIB) Headlines

From GuruFocus

Biogen Inc Investor Day Transcript

By GuruFocus Research 01-22-2024

Q2 2023 Biogen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q2 2021 Biogen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q4 2021 Biogen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q3 2023 Biogen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Biogen Inc at SVB Leerink CNS Forum (Virtual) Transcript

By GuruFocus Research 01-22-2024